III.J.20. Medical Countermeasures for Brucellosis. Develop medical countermeasures against the biological warfare threat of Brucella, the causative agent of brucellosis, a systemic bacterial disease characterized by fever, weakness, depression, and generalized aching. By FY97, demonstrate the feasibility of producing a vaccine against brucellosis using one species as the model approach (milestone 0). By FY99, transition to advanced development a vaccine that will protect 80 percent of immunized personnel against an aerosol challenge of any species of Brucella and will induce minimum reactogenicity in soldiers when immunized (milestone 1).
Supports: Army Modernization Plan, Medical Annex OProtect, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).
|STO Manager:||TSO:||TRADOC POC:|
|Dr. Anna Johnson-Winegar||MAJ Mark Seymour||CPT Ensor|